{"id":32560,"date":"2025-08-15T07:29:40","date_gmt":"2025-08-15T06:29:40","guid":{"rendered":"https:\/\/by-tv.co.uk\/?p=32560"},"modified":"2025-08-15T07:29:40","modified_gmt":"2025-08-15T06:29:40","slug":"tip-1-diyabetin-gelisimini-yavaslatan-ilaca-onay-bagisiklik-sistemi-yeniden-egitiliyor","status":"publish","type":"post","link":"https:\/\/by-tv.co.uk\/en\/tip-1-diyabetin-gelisimini-yavaslatan-ilaca-onay-bagisiklik-sistemi-yeniden-egitiliyor\/","title":{"rendered":"Tip 1 Diyabetin Geli\u015fimini Yava\u015flatan \u0130laca Onay “Ba\u011f\u0131\u015f\u0131kl\u0131k Sistemi Yeniden E\u011fitiliyor”"},"content":{"rendered":"

\u0130ngiltere’de Tip 1 diyabetin ilerlemesini yava\u015flatan yeni bir ilaca ruhsat verildi. Teplizumab adl\u0131 ila\u00e7, hastalar\u0131n ins\u00fclin enjeksiyonlar\u0131na ba\u015flamas\u0131n\u0131 geciktirerek daha uzun s\u00fcre normal bir ya\u015fam s\u00fcrmelerine olanak tan\u0131yor.<\/p>\n

Birle\u015fik Krall\u0131k\u2019ta \u0130lk Onay<\/h4>\n

\u0130la\u00e7 ve Sa\u011fl\u0131k \u00dcr\u00fcnleri D\u00fczenleme Kurumu (MHRA), teplizumab\u2019\u0131n Birle\u015fik Krall\u0131k’ta kullan\u0131m\u0131n\u0131 onaylad\u0131. B\u00f6ylece Birle\u015fik Krall\u0131k, Avrupa\u2019da bu ilaca ruhsat veren ilk \u00fclke oldu. Halihaz\u0131rda ABD\u2019de de onayl\u0131 olan teplizumab, \u00e7ocuklar da dahil olmak \u00fczere sekiz ya\u015f ve \u00fczeri bireylerde uygulanabilecek.<\/p>\n

\u0130la\u00e7, tip 1 diyabetin \u00fc\u00e7\u00fcnc\u00fc evresine ge\u00e7i\u015fi ortalama \u00fc\u00e7 y\u0131l geciktirebiliyor. Bu, hastal\u0131\u011f\u0131n tam olarak ortaya \u00e7\u0131kmas\u0131ndan \u00f6nceki \u201cy\u00fcksek riskli\u201d ikinci evredeki hastalara uygulanacak.<\/p>

\"\"<\/a><\/div>\n

Ba\u011f\u0131\u015f\u0131kl\u0131k Sistemi Yeniden E\u011fitiliyor<\/h4>\n

Teplizumab, ba\u011f\u0131\u015f\u0131kl\u0131k sistemini pankreastaki ins\u00fclin \u00fcreten beta h\u00fccrelerine sald\u0131rmamas\u0131 i\u00e7in “yeniden e\u011fitiyor”. \u0130lac\u0131n en az 30 dakika s\u00fcren damar i\u00e7i inf\u00fczyon \u015feklinde, 14 g\u00fcn boyunca aral\u0131ks\u0131z uygulanmas\u0131 gerekiyor.<\/p>\n

Birmingham \u00dcniversitesi ve Queen Elizabeth Hastanesi\u2019nden Diyabet Profes\u00f6r\u00fc Parth Narendran, ilac\u0131n etkisini \u015fu s\u00f6zlerle a\u00e7\u0131klad\u0131:
\n\u201cTeplizumab, pankreas\u0131n ins\u00fclin \u00fcretmesini engelleyen ba\u011f\u0131\u015f\u0131kl\u0131k sald\u0131r\u0131lar\u0131n\u0131 durduruyor. Bu sayede hastalar, ins\u00fclin enjeksiyonlar\u0131na ba\u015flamadan \u00f6nce daha uzun s\u00fcre normal ya\u015fam s\u00fcrebiliyor. Ayn\u0131 zamanda hastal\u0131kla ani bir \u015fekilde y\u00fczle\u015fmek yerine, ilerleyi\u015fine haz\u0131rlanma f\u0131rsat\u0131 da sunuyor.\u201d<\/p>\n

Hayat\u0131 Kolayla\u015ft\u0131racak Bir D\u00f6n\u00fcm Noktas\u0131<\/h4>\n

Tip 1 diyabet, v\u00fccudun ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin pankreastaki ins\u00fclin \u00fcreten h\u00fccrelere sald\u0131rmas\u0131yla ortaya \u00e7\u0131k\u0131yor. Bu durum, kan \u015fekeri seviyelerinin tehlikeli \u015fekilde y\u00fckselmesine neden olabiliyor. Yakla\u015f\u0131k 400.000 ki\u015finin bu hastal\u0131kla ya\u015fad\u0131\u011f\u0131 Birle\u015fik Krall\u0131k’ta, hastalar genellikle ya\u015fam boyu ins\u00fclin enjeksiyonlar\u0131na ba\u011f\u0131ml\u0131 kal\u0131yor.<\/p>\n

Sanofi’nin Birle\u015fik Krall\u0131k ve \u0130rlanda Genel \u0130la\u00e7lar Genel M\u00fcd\u00fcr\u00fc Ahmed Moussa, \u201cY\u00fcz y\u0131l \u00f6nce ins\u00fclinin ke\u015ffi diyabet bak\u0131m\u0131nda bir devrimdi. Bug\u00fcnk\u00fc geli\u015fme de ayn\u0131 derecede b\u00fcy\u00fck bir ad\u0131m\u201d dedi.<\/p>\n

NHS \u0130\u00e7in De\u011ferlendirme S\u00fcreci Ba\u015flayacak<\/h4>\n

MHRA\u2019n\u0131n onay\u0131n\u0131n ard\u0131ndan, Ulusal Sa\u011fl\u0131k Hizmetleri\u2019nin (NHS) ila\u00e7lar\u0131 finanse edip etmeyece\u011fine karar veren NICE (National Institute for Health and Care Excellence) taraf\u0131ndan teplizumab\u2019\u0131n maliyet-etkinlik analizi yap\u0131lacak.<\/p>\n

Diabetes UK Ara\u015ft\u0131rma Direkt\u00f6r\u00fc Dr. Elizabeth Robertson, geli\u015fmeyi “tip 1 diyabet tedavisinde bir d\u00f6n\u00fcm noktas\u0131” olarak nitelendirerek, \u201c\u0130lk kez hastal\u0131\u011f\u0131n k\u00f6kenine y\u00f6nelik bir tedaviye sahibiz. \u00dc\u00e7 y\u0131l boyunca hastal\u0131\u011f\u0131n zorluklar\u0131ndan uzak bir ya\u015fam imk\u00e2n\u0131 sunuyor\u201d ifadelerini kulland\u0131.<\/p>\n

Breakthrough T1D vakf\u0131n\u0131n CEO\u2019su Karen Addington ise, \u201cY\u0131llar s\u00fcren ara\u015ft\u0131rma, klinik deneme ve geli\u015ftirme \u00e7al\u0131\u015fmalar\u0131n\u0131n ard\u0131ndan bu \u00f6nemli ilerlemeyi g\u00f6rmek mutluluk verici\u201d dedi.<\/p>\n

Kaynak: LBC <\/strong><\/p>\n

\"\"<\/a><\/div>","protected":false},"excerpt":{"rendered":"

\u0130ngiltere’de Tip 1 diyabetin ilerlemesini yava\u015flatan yeni bir ilaca ruhsat verildi. Teplizumab adl\u0131 ila\u00e7, hastalar\u0131n ins\u00fclin enjeksiyonlar\u0131na ba\u015flamas\u0131n\u0131 geciktirerek daha uzun s\u00fcre normal bir ya\u015fam s\u00fcrmelerine olanak tan\u0131yor. Birle\u015fik Krall\u0131k\u2019ta \u0130lk Onay \u0130la\u00e7 ve Sa\u011fl\u0131k \u00dcr\u00fcnleri D\u00fczenleme Kurumu (MHRA), teplizumab\u2019\u0131n Birle\u015fik Krall\u0131k’ta kullan\u0131m\u0131n\u0131 onaylad\u0131. B\u00f6ylece Birle\u015fik Krall\u0131k, Avrupa\u2019da bu ilaca ruhsat veren ilk \u00fclke oldu. Halihaz\u0131rda ABD\u2019de de onayl\u0131 olan teplizumab, \u00e7ocuklar da dahil olmak \u00fczere sekiz ya\u015f ve \u00fczeri bireylerde uygulanabilecek. \u0130la\u00e7, tip 1 diyabetin \u00fc\u00e7\u00fcnc\u00fc evresine ge\u00e7i\u015fi ortalama \u00fc\u00e7 y\u0131l geciktirebiliyor. Bu, hastal\u0131\u011f\u0131n tam olarak ortaya \u00e7\u0131kmas\u0131ndan \u00f6nceki \u201cy\u00fcksek riskli\u201d ikinci evredeki hastalara uygulanacak. Ba\u011f\u0131\u015f\u0131kl\u0131k Sistemi Yeniden E\u011fitiliyor […]<\/p>\n","protected":false},"author":1,"featured_media":32561,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[5269],"tags":[],"class_list":["post-32560","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-birlesik-krallik"],"_links":{"self":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts\/32560","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/comments?post=32560"}],"version-history":[{"count":1,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts\/32560\/revisions"}],"predecessor-version":[{"id":32562,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts\/32560\/revisions\/32562"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/media\/32561"}],"wp:attachment":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/media?parent=32560"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/categories?post=32560"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/tags?post=32560"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}